BR0207399A - Método de terapia com células para o tratamento de tumores - Google Patents

Método de terapia com células para o tratamento de tumores

Info

Publication number
BR0207399A
BR0207399A BR0207399-4A BR0207399A BR0207399A BR 0207399 A BR0207399 A BR 0207399A BR 0207399 A BR0207399 A BR 0207399A BR 0207399 A BR0207399 A BR 0207399A
Authority
BR
Brazil
Prior art keywords
cells
antigen
responses
specific
vivo
Prior art date
Application number
BR0207399-4A
Other languages
English (en)
Inventor
Juli Degraw
Ann Moriarty
Didier J Leturcq
Michael R Jackson
Per A Peterson
Marja Heiskala
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0207399A publication Critical patent/BR0207399A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)

Abstract

"MéTODO DE TERAPIA COM CéLULAS PARA O TRATAMENTO DE TUMORES". As respostas de células T são com freq³ência diminuídas em seres humanos com um sistema imune comprometido. Foi desenvolvido um método para isolar, estimular e expandir precursores de linfócitos T citotóxicos nativos (CTLP) para efetuadores específicos para antígenos, capazes de lisar células de tumor in vivo. Este protocolo ex vivo produz efetuadores completamente funcionais. As células apresentando antígenos artificiais (AAPCS; Drosophila melanogaster) transfectadas com classe 1 de HLA humano e moléculas acessórias definidas, são usadas para estimular células CD8^ +^ de tanto doadores normais como pacientes com câncer. As moléculas de classe I expressas em uma alta densidade sobre a superfície das células de Drosophila são vazias, permitindo um carregamento eficiente de peptídeos múltiplos que resulta na geração de respostas policionais reconhecendo células de tumor endogenamente expressando os peptídeos específicos. As respostas geradas são robustas, específicas para antígeno e reprodutíveis se o epitopo do peptídeo for um imunógeno definido. Este sistema de expressão de antígeno artificial pode ser adaptado para tratar a maior parte dos cânceres em uma maioria significante da população.
BR0207399-4A 2001-02-20 2002-02-19 Método de terapia com células para o tratamento de tumores BR0207399A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27025201P 2001-02-20 2001-02-20
PCT/US2002/005748 WO2002065992A2 (en) 2001-02-20 2002-02-19 A cell therapy method for the treatment of tumors

Publications (1)

Publication Number Publication Date
BR0207399A true BR0207399A (pt) 2004-10-26

Family

ID=23030546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207399-4A BR0207399A (pt) 2001-02-20 2002-02-19 Método de terapia com células para o tratamento de tumores

Country Status (21)

Country Link
US (2) US20030077248A1 (pt)
EP (3) EP1377251B1 (pt)
JP (3) JP2006510567A (pt)
KR (2) KR100962544B1 (pt)
CN (1) CN1571834B (pt)
AT (1) ATE396691T1 (pt)
BR (1) BR0207399A (pt)
CA (2) CA2438754C (pt)
DE (1) DE60226853D1 (pt)
DK (1) DK2016930T3 (pt)
EA (1) EA013944B1 (pt)
ES (2) ES2643582T3 (pt)
HU (1) HUP0402656A3 (pt)
IL (3) IL157366A0 (pt)
MX (1) MXPA03007503A (pt)
NO (1) NO334885B1 (pt)
NZ (1) NZ527683A (pt)
PL (1) PL206976B1 (pt)
PT (1) PT1377251E (pt)
WO (1) WO2002065992A2 (pt)
ZA (1) ZA200307327B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
ES2643582T3 (es) 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ES2502366T3 (es) * 2001-03-09 2014-10-03 Board Of Regents, The University Of Texas System Inducción de inmunidad tumoral por variantes de proteína de unión a folato
US8802618B2 (en) * 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
DE60334474D1 (de) * 2002-07-12 2010-11-18 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes
EP1645183B1 (en) 2003-06-16 2013-03-13 Kyushu University, National University Corporation Process for producing human-origin immunocompetent cell
JP2005139118A (ja) * 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
WO2012087943A2 (en) * 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
CN103667189B (zh) * 2013-09-24 2015-10-28 上海宇研生物技术有限公司 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法
CA3017170C (en) * 2014-09-17 2021-03-23 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
WO2016196506A1 (en) 2015-05-29 2016-12-08 Galena Biopharma, Inc. PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRα-EXPRESSING TUMORS
EP3463438B1 (en) 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
WO2025171250A1 (en) * 2024-02-08 2025-08-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Nyeso1 tcr for t-cell therapy and methods of use
CN121472152B (zh) * 2026-01-09 2026-04-03 无锡市第二人民医院 细胞药物及其在膀胱癌药物的药效评价方法及应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4473642A (en) * 1981-04-29 1984-09-25 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US4407945A (en) * 1981-04-29 1983-10-04 Immunex Corporation Constitutive production of interleukin 2 by a T cell hybridoma
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4992367A (en) * 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
CA2069541C (en) 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6017719A (en) 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5595881A (en) 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
CA2214649C (en) * 1995-03-08 2007-06-12 Zeling Cai Antigen presenting system and methods for activation of t-cells
US5759783A (en) 1995-03-14 1998-06-02 Ludwig Institute For Cancer Research Method of screening for cancer by detecting messenger RNA for a MAGE-XP gene
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
ES2278390T3 (es) * 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
JP2002500872A (ja) * 1998-01-26 2002-01-15 ジェンザイム・コーポレーション 免疫エフェクター細胞ハイブリッド
WO1999054345A1 (en) 1998-04-21 1999-10-28 Thomas Jefferson University Cd8 antagonists
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
HK1041312B (en) * 1999-04-16 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Method for the detection of antigen specific t-cells
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
AU3823601A (en) * 2000-02-11 2001-08-20 Dana Farber Cancer Inst Inc Cytotoxic t lymphocytes activated by dendritic cell hybrids
WO2002004603A2 (de) * 2000-07-10 2002-01-17 Eppendorf Ag Verfahren zur modifizierung von biologischen zellen
ES2643582T3 (es) 2001-02-20 2017-11-23 Janssen Pharmaceuticals, Inc. Antígeno de Drosophila artificial que presenta célula para preparar suspensión de células CD8 para su uso en el tratamiento del cáncer

Also Published As

Publication number Publication date
HUP0402656A3 (en) 2012-03-28
NO334885B1 (no) 2014-06-30
EP2848255B1 (en) 2017-08-23
KR100971266B1 (ko) 2010-07-20
EP1377251A2 (en) 2004-01-07
ATE396691T1 (de) 2008-06-15
EP2016930A2 (en) 2009-01-21
EA013944B1 (ru) 2010-08-30
JP5634415B2 (ja) 2014-12-03
HK1208376A1 (en) 2016-03-04
NZ527683A (en) 2006-06-30
DE60226853D1 (de) 2008-07-10
IL219223A0 (en) 2012-06-28
KR20090061081A (ko) 2009-06-15
US20090305418A1 (en) 2009-12-10
HUP0402656A2 (hu) 2005-03-29
PT1377251E (pt) 2008-08-05
NO20033674L (no) 2003-10-17
HK1058485A1 (en) 2004-05-21
CA2438754A1 (en) 2002-08-29
CN1571834B (zh) 2013-03-20
NO20033674D0 (no) 2003-08-19
KR100962544B1 (ko) 2010-06-14
EP2848255A1 (en) 2015-03-18
CA2438754C (en) 2014-10-07
WO2002065992A2 (en) 2002-08-29
US20030077248A1 (en) 2003-04-24
DK2016930T3 (en) 2014-12-08
EP1377251B1 (en) 2008-05-28
ZA200307327B (en) 2005-03-30
KR20030077029A (ko) 2003-09-29
IL157366A (en) 2013-04-30
PL369971A1 (pl) 2005-05-02
JP2012097117A (ja) 2012-05-24
EP2016930B1 (en) 2014-10-15
IL157366A0 (en) 2004-02-19
EA200300815A1 (ru) 2004-06-24
JP2010222352A (ja) 2010-10-07
MXPA03007503A (es) 2004-10-15
WO2002065992A3 (en) 2003-02-13
US9222071B2 (en) 2015-12-29
ES2643582T3 (es) 2017-11-23
CA2698079A1 (en) 2002-08-29
IL219223B (en) 2018-05-31
JP2006510567A (ja) 2006-03-30
EP1377251A4 (en) 2006-01-11
CN1571834A (zh) 2005-01-26
EP2016930A3 (en) 2009-09-02
PL206976B1 (pl) 2010-10-29
ES2306771T3 (es) 2008-11-16
CA2698079C (en) 2015-01-13

Similar Documents

Publication Publication Date Title
BR0207399A (pt) Método de terapia com células para o tratamento de tumores
EP1470821A3 (en) Cell therapy method for the treatment of tumours
Gilboa The makings of a tumor rejection antigen
Pardoll Inducing autoimmune disease to treat cancer
Vatakis et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells
Bekeschus et al. Potentiating anti-tumor immunity with physical plasma
DENKINS et al. Exposure of mice to UV‐B radiation suppresses delayed hypersensitivity to Candida albicans
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
BR0115795A (pt) Métodos para introduzir uma molécula no citosol de uma célula, para o tratamento ou prevenção de uma doença, distúrbio ou infecção em um paciente, para estimular uma resposta imune, célula, e, uso de uma molécula de transferência e/ou um agente fotossensibilizante
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
PL2327763T3 (pl) Generowanie komórek T specyficznych względem antygenu
ATE235558T1 (de) Transformation von tierischen somatischen zellen mittels partikeln
DK0749323T3 (da) Fremgangsmåder til modulering af T-celle-anergi
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
ES2187568T3 (es) Vacuna viva para el tratamiento de enfermedades tumorales.
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
Madsen et al. Limiting glioma development by photodynamic therapy-generated macrophage vaccine and allo-stimulation: an in vivo histological study in rats
BRPI0415519A (pt) método para aumento das respostas de célula t citotóxica cd8+ e para tratamento de esclerose múltipla
Whitacre et al. Regulation of Autoreactive T Cell Function by Oral Tolerance to Self‐Antigens
Molnar et al. 23.2. Adaptive immune response
Lutz et al. Studies of myosin isoforms in muscle cells: single cell mechanics and gene transfer
Arnold et al. Cell-mediated immunity in thyroid-associated ophthalmopathy

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: JOHNSON & JOHNSON (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/0783 (2010.01), A61K 39/00 (2006.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]